Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;28(4):757-765.
doi: 10.1038/s41593-025-01895-5. Epub 2025 Mar 4.

Neuronal somatic mutations are increased in multiple sclerosis lesions

Affiliations

Neuronal somatic mutations are increased in multiple sclerosis lesions

Allan Motyer et al. Nat Neurosci. 2025 Apr.

Abstract

Neuroinflammation underpins neurodegeneration and clinical progression in multiple sclerosis (MS), but knowledge of processes linking these disease mechanisms remains incomplete. Here we investigated somatic single-nucleotide variants (sSNVs) in the genomes of 106 single neurons from post-mortem brain tissue of ten MS cases and 16 controls to determine whether somatic mutagenesis is involved. We observed an increase of 43.9 sSNVs per year in neurons from chronic MS lesions, a 2.5 times faster rate than in neurons from normal-appearing MS and control tissues. This difference was equivalent to 1,291 excess sSNVs in lesion neurons at 70 years of age compared to controls. We performed mutational signature analysis to investigate mechanisms underlying neuronal sSNVs and identified a signature characteristic of lesions with a strong, age-associated contribution to sSNV counts. This research suggests that neuroinflammation is mutagenic in the MS brain, potentially contributing to disease progression.

PubMed Disclaimer

Conflict of interest statement

Competing interests: B.Y., I.H., W.T., W.I.A.S. and B.W. are employees of BGI-Australia. M.B. has received institutional support for research or speaking from Alexion, Biogen, BMS, Merck, Novartis, Roche and Sanofi Genzyme. The other authors declare no competing interests.

References

    1. GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 269–285 (2019). - DOI
    1. Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. 26, 1816–1821 (2020). - PubMed - PMC - DOI
    1. Cree, B. A. C. et al. Secondary progressive multiple sclerosis: new insights. Neurology 97, 378–388 (2021). - PubMed - PMC - DOI
    1. Correale, J., Gaitan, M. I., Ysrraelit, M. C. & Fiol, M. P. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain 140, 527–546 (2017). - PubMed
    1. Faissner, S., Plemel, J. R., Gold, R. & Yong, V. W. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat. Rev. Drug Discov. 18, 905–922 (2019). - PubMed - DOI

LinkOut - more resources